Cleveland BioLabs, Inc. (NASDAQ:CBLI) released its quarterly earnings results on Tuesday. The biotechnology company reported ($0.11) EPS for the quarter, Bloomberg Earnings reports. Cleveland BioLabs had a negative net margin of 253.09% and a negative return on equity of 61.18%.

Cleveland BioLabs (NASDAQ:CBLI) traded down $0.27 during mid-day trading on Wednesday, reaching $2.39. The company’s stock had a trading volume of 119,600 shares, compared to its average volume of 433,093. Cleveland BioLabs has a twelve month low of $1.22 and a twelve month high of $5.55.

WARNING: This story was originally posted by American Banking News and is the property of of American Banking News. If you are viewing this story on another domain, it was illegally stolen and republished in violation of United States and international trademark & copyright law. The correct version of this story can be viewed at https://www.americanbankingnews.com/2017/11/15/cleveland-biolabs-inc-cbli-posts-quarterly-earnings-results.html.

Separately, ValuEngine upgraded Cleveland BioLabs from a “sell” rating to a “hold” rating in a research note on Friday, August 11th.

A hedge fund recently raised its stake in Cleveland BioLabs stock. Vanguard Group Inc. increased its position in shares of Cleveland BioLabs, Inc. (NASDAQ:CBLI) by 106.9% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 170,088 shares of the biotechnology company’s stock after buying an additional 87,885 shares during the period. Vanguard Group Inc. owned about 1.51% of Cleveland BioLabs worth $501,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 4.58% of the company’s stock.

About Cleveland BioLabs

Cleveland BioLabs, Inc (CBLI) is a biopharmaceutical company. The Company is engaged in developing approaches to activate the immune system and address serious medical needs. Its platform of Toll-like immune receptor activators has applications in mitigation of radiation injury and immuno-oncology. Its advanced product candidate is Entolimod, an immuno-stimulatory agent, which it is developing as a radiation countermeasure and an immunotherapy for oncology and other indications.

Earnings History for Cleveland BioLabs (NASDAQ:CBLI)

Receive News & Ratings for Cleveland BioLabs Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cleveland BioLabs Inc. and related companies with MarketBeat.com's FREE daily email newsletter.